Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia

被引:16
作者
Cao, Tingyong [1 ]
Ye, Yuanxin [2 ]
Liao, Hongyan [2 ]
Shuai, Xiao [1 ]
Jin, Yongmei [2 ]
Sub, Jun [2 ]
Zheng, Qin [2 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
acute myeloid leukemia; disease-free survival; overall survival; prognosis; relative fluorescence intensity of chemokine Receptor 4; relapse; UNFAVORABLE PROGNOSIS; AML; MICROENVIRONMENT; CHEMORESISTANCE; OVEREXPRESSION; CLASSIFICATION; INHIBITION; RATIONALE;
D O I
10.1097/MD.0000000000015948
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CXC chemokine receptor 4 (CXCR4) expression on acute myeloid leukemia (AML) cells correlated with stromal cell derived factor-1 alpha (SDF-1 alpha) and retained hematopoietic progenitors and leukemia cells within the bone marrow microenvironment. Here, we examined CXCR4 expression in 134 de novo AML and 21 controls by flow cytometry, evaluated the relationship between CXCR4 expression and clinical characteristics, and elucidated the prognostic significance of CXCR4 expression in AML prospectively. We found that the CXCR4 expression was significantly higher in AML patients than controls (P=.000). One hundred thirty four cases of de novo AML patients were divided into 2 groups according to the median of CXCR4 relative fluorescence intensity (RFI). CXCR4 high group (RFI>4.23) had markedly shorter overall survival (OS) and disease-free survival (DFS) than CXCR4 low group (RFI <= 4.23) in 106 AML patients who received chemotherapy (P=.002;.026, respectively). Furthermore, in the 87 non-M3 patients who received induction therapy, there was a significant decrease for OS but not for DFS in the CXCR4 high group (P=.047 and.178, respectively). Moreover, high levels of CXCR4 expression independently increased the risk of relapse in both all AML and non-M3 patients who achieved complete remission (CR) after chemotherapy (odds ratio=1.090, P=.010; odds ratio=1.068, P=.048, respectively). Collectively, our data suggest that CXCR4 overexpression was an independent prognostic factor for disease relapse and poorer OS in both all AML and non-M3 patients. CXCR4 expression levels can be determined at disease presentation by the flow rapidly and easily. As such, CXCR4 could be used as a potential therapeutic target in AML patients with poor prognosis.
引用
收藏
页数:9
相关论文
共 37 条
[1]  
Ahn JY, 2013, APPL IMMUNOHISTO M M, V21, P79, DOI 10.1097/PAI.0b013e3182606f4d
[2]   VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia [J].
Bae, Mi Hyun ;
Oh, Sung-Hee ;
Park, Chan-Jeoung ;
Lee, Bo-Ra ;
Kim, Young Jin ;
Cho, Young-Uk ;
Jang, Seongsoo ;
Lee, Je-Hwan ;
Kim, Nayoung ;
Park, Sang Hyuk ;
Lim, Ji-Hun ;
Seo, Eul-Ju ;
Lee, Kyoo-Hyung .
ANNALS OF HEMATOLOGY, 2015, 94 (10) :1631-1638
[3]   The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway [J].
Beider, Katia ;
Rosenberg, Evgenia ;
Bitner, Hanna ;
Shimoni, Avichai ;
Leiba, Merav ;
Koren-Michowitz, Maya ;
Ribakovsky, Elena ;
Klein, Shiri ;
Olam, Devorah ;
Weiss, Lola ;
Wald, Hanna ;
Abraham, Michal ;
Galun, Eithan ;
Peled, Amnon ;
Nagler, Arnon .
CLINICAL CANCER RESEARCH, 2017, 23 (07) :1733-1747
[4]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[5]   CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia [J].
Chen, Ye ;
Jacamo, Rodrigo ;
Konopleva, Marina ;
Garzon, Ramiro ;
Croce, Carlo ;
Andreeff, Michael .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (06) :2395-2407
[6]   High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia [J].
Crazzolara, R ;
Kreczy, A ;
Mann, G ;
Heitger, A ;
Eibl, G ;
Fink, FM ;
Möhle, R ;
Meister, B .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) :545-553
[7]   Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].
Doehner, Hartmut ;
Estey, Elihu ;
Grimwade, David ;
Amadori, Sergio ;
Appelbaum, Frederick R. ;
Buechner, Thomas ;
Dombret, Herve ;
Ebert, Benjamin L. ;
Fenaux, Pierre ;
Larson, Richard A. ;
Levine, Ross L. ;
Lo-Coco, Francesco ;
Naoe, Tomoki ;
Niederwieser, Dietger ;
Ossenkoppele, Gert J. ;
Sanz, Miguel ;
Sierra, Jorge ;
Tallman, Martin S. ;
Tien, Hwei-Fang ;
Wei, Andrew H. ;
Lowenberg, Bob ;
Bloomfield, Clara D. .
BLOOD, 2017, 129 (04) :424-447
[8]   Acute myeloid leukaemia in adults [J].
Ferrara, Felicetto ;
Schiffer, Charles A. .
LANCET, 2013, 381 (9865) :484-495
[9]   Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials [J].
Grimwade, David ;
Hills, Robert K. ;
Moorman, Anthony V. ;
Walker, Helen ;
Chatters, Stephen ;
Goldstone, Anthony H. ;
Wheatley, Keith ;
Harrison, Christine J. ;
Burnett, Alan K. .
BLOOD, 2010, 116 (03) :354-365
[10]  
GUALBERTO A, 2017, BLOOD S1, V130